Imricor Medical Systems’ (ASX:IMR) shares were up 2.17% in lunchtime trades on news the company is one step closer to launching a medical trial in Switzerland to test its MRI-machine-compatible ‘VISABL-AFL’ heart devices.
Imricor’s relationship with the Swiss Lausanne University Hospital (LUH) has further advanced as the company wins approval from its ethics committee to conduct such a trial.
LUH requires one more approval to participate in the trial; Swiss entity Swissmedic needs to give the final greenlight.
Should that occur, LUH will become the second university hospital alongside John Hopkins to join an Imricor trial.
The entity is confident it can win approval from Swissmedic – such that LUH already has a built-out facility on-site to cater specifically to Imricor’s products.
After LUH and John Hopkins, Imricor is hoping to angle into Amsterdam and South Paris.
“Our clinical team’s plans for executing an efficient multi-centre study for VISABL-AFL is on track, which means our FDA process and US launch are also on track,” Imricor chief Steve Wedan said.
That US launch is the ultimate prize for Imricor – which needs FDA approval to kick off.
The ultimate value proposition Imricor puts forward is that it can advance the utility of an MRI machine where cardiac concerns are involved by having safe-to-use devices active in the body while the scan takes place.
MRI machines ultimately rely on extremely strong magnetic fields to image the human body and are notorious for being dangerous to operate when metallic objects are in the room.
MRIs are perhaps the most advanced machine humanity has ever commercialised on a mass scale.
Imricor (ASX:IMR) shares were up 2.17% to 47cps in lunchtime trades.